Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

IND Swift Laboratories Ltd (ISLB)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
117.80 -5.55    -4.50%
02:55:25 - Real-time Data. Currency in INR ( Disclaimer )
Type:  Equity
Market:  India
ISIN:  INE915B01019 
S/N:  INDSWFTLAB
  • Volume: 348,904
  • Bid/Ask: 117.55 / 117.80
  • Day's Range: 116.30 - 124.10
Ind-Swift Labs 117.80 -5.55 -4.50%

IND Swift Laboratories Ltd Company Profile

 
Get an in-depth profile of IND Swift Laboratories Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

1496

Equity Type

ORD

Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) and advanced intermediates in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, and antineoplastic, as well as various products for ADHD symptoms. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, Clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services. The company also exports its products. The company was incorporated in 1995 and is headquartered in Manimajra, India.

Contact Information

Address Shivalik Enclave SCO 850
NAC Manimajra, 160101
India
Phone 91 17 2506 1850
Fax 91 17 2273 0504

Top Executives

Name Age Since Title
Rishav Mehta 31 2010 Executive Director
Navrattan Munjal 70 1995 Chairman & MD
Himanshu Jain 40 2010 Joint MD & Whole Time Director
Sri Prakash Sharma 67 2012 Non-Executive Independent Director
Rajinder Kumar Gupta - 2021 Non-Executive Independent Director
Neerja Chathley - 2019 Non-Executive Independent Woman Director
Ashwani Kumar Vig 73 2020 Non-Executive Independent Director
Sahil Munjal 43 2020 President of Operations & Special Assignments and Executive Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ISLB Comments

Write your thoughts about IND Swift Laboratories Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
rakushree Roul
rakushree Roul Oct 21, 2021 9:35AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hello, i lost 2000 in CNC, what happened inside the company.
Tane Rathore
Tane Rathore Sep 30, 2020 2:06PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
80+ target insight
Devender Singh Negi
Devender Singh Negi Sep 18, 2020 11:06AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
International CARE rating improved...
Neha Gupta
Neha Gupta Jun 25, 2018 1:23PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
See it crossed hundreds..
Neha Gupta
Neha Gupta Mar 23, 2018 5:10PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Strong buy, stock has capabilities to go upto 90. Upcoming quarter will be great as company is getting great funding
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email